에 대한 최신 뉴스 Evolent Health (NYSE:EVH) 주식

Evolent Health

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Asia

Mid Cap

News

Movers

ASTS

IOVA

LUMN

PSNY

SFTBF

SMTC

UPST

이들 10개의 중형주는 8월에 가장 좋은 성과를 보였다. 이 주식들이 귀하의 포트폴리오에 포함되어 있나요? 1. 폴스타 오토모티브 홀딩(NASDAQ:PSNY)의 주식이 8월에 74.19% 급등했다. 이는 2분기 강력한 인도량을 발표한 후 발생한 일이다.

AST 스페이스모바일 및 폴스타는 8월에 최고 성과를 보여준 10개 중형주 중 일부

CRDO

GRFS

LCID

NUVL

PRCT

다음은 지난주 큰 폭의 상승세를 보인 8개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 1. 루시드 그룹(NASDAQ:LCID)의 주식이 32.91% 급등했다. 이 회사는 루시드 파이낸셜 서비시스(Lucid Financial Services)가 캐나다의 다양한 금융 옵션에 임대를 추가했다고 발표했다. 경제와 금리 인하에 대한 파월 의장의 발언도 심리를 개선했다. 

루시드 및 그리폴스는 지난주 최고 성과를 보여준 8개 중형주 중 일부 (8월 18일-8월 24일)

Evolent Health Inc

EVENT HOSPITALITY & ENTMT by EVENT HOSPITALITY & ENTMT LTD.

EVT Ltd

Morgan Stanley ETF Trust Eaton Vance High Yield ETF

These ten mid-cap stocks were the best performers in August. Are they in your portfolio?
<ol>
<li>Polestar Automotive Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) shares jumped 74.19%. It reported <a href="https://www.benzinga.com//node/40629765" target="_blank" rel="noreferrer noopener">strong second-quarter deliveries</a>.</li>
<li>Upstart Holdings, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) stock escalated 67.32% after the company reported better-than-<a href="https://www.benzinga.com//node/40322490" target="_blank" rel="noreferrer noopener">expected second-quarter results</a>.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares rocketed 58.13%. It reported <a href="https://www.benzinga.com//node/40204727" target="_blank" rel="noreferrer noopener">mixed second-quarter results</a>.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) shares rose 52.46%. The company reported a better-than-consensus <a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener">second-quarter loss per share</a>.</li>
<li>Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) stock gained 51.17%. The stock got a boost from investments by Google<a href="https://www.benzinga.com//node/40419923" target="_blank" rel="noreferrer noopener"> and </a><a href="https://www.benzinga.com//node/40419923" target="_blank" rel="noreferrer noopener">SoftBank Group Corp</a><a href="https://www.benzinga.com//node/40419923" target="_blank" rel="noreferrer noopener"> (OTCPK: SFTBF)</a>.</li>
<li>Clear Secure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) shares were up 46.81%. It reported <a href="https://www.benzinga.com//node/40181525" target="_blank" rel="noreferrer noopener">better-than-expected quarterly results</a>.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock jumped 42.89%. The company issued upbeat guidance for 2024 and 2025 and better-than-<a href="https://www.benzinga.com//node/40288203" target="_blank" rel="noreferrer noopener">expected second-quarter earnings</a>.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) shares escalated 42.51%. The company initiated an auction process after receiving takeover inquiries from private<a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener"> equity firms and healthcare providers</a>.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) stock rose 42.23%. It reported a <a href="https://www.benzinga.com//node/40587744" target="_blank" rel="noreferrer noopener">second-quarter earnings beat</a>.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares grew 42.07%. The company announced that it&#8217;s on track to launch five <a href="https://www.benzinga.com//node/40398813" target="_blank" rel="noreferrer noopener">satellites in early September</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40764288/affirm-shopify-and-starbucks-were-among-top-10-large-cap-best-performers-for-august-are-the-others" target="_blank" rel="noreferrer noopener">Affirm, Shopify And Starbucks Were Among Top 10 Large Cap Best Performers For August: Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40764325/intel-moderna-and-dollar-general-were-among-top-10-large-cap-losers-in-august-are-the-others-in-yo" target="_blank" rel="noreferrer noopener">Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Company

AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and maintains $33 price target.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Evolent Health, Maintains $33 Price Target

RBC Capital analyst Sean Dodge reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Outperform and maintains $42 price target.

Reiteration

RBC Capital Reiterates Outperform on Evolent Health, Maintains $42 Price Target

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares soared 32.91%. The company announced that Lucid Financial Services has added leasing to its range of <a href="https://www.benzinga.com//node/40466130" target="_blank" rel="noreferrer noopener">financing options in Canada</a>. Fed Chair Powell&#8217;s comments about the economy and interest rate cuts also improved the sentiment.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) stock rose 32.04% after it reported second-<a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener">quarter financial results</a>.</li>
<li>PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) shares escalated 22.67% after the company announced FDA 510(k) clearance of <a href="https://www.benzinga.com//node/40481411" target="_blank" rel="noreferrer noopener">its HYDROS Robotic system</a>.</li>
<li>Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) shares were up 20.02%.</li>
<li>Evolent Health, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock upped 19.98% following a report suggesting <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener">the company is exploring a sale</a>.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares jumped 19.50% following a report suggesting that Brookfield Asset Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) is seeking debt financing to acquire the company.</li>
<li>Nuvalent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) stock increased 19.33%.</li>
<li>Amer Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) stock escalated 16.60% after it reported better-than-expected second-quarter <a href="https://www.benzinga.com//node/40466836" target="_blank" rel="noreferrer noopener">results and raised its FY24 EPS outlook</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40543876/zoom-video-microstrategy-and-target-were-among-top-11-large-cap-gainers-last-week-aug-18-aug-24-ar" target="_blank" rel="noreferrer noopener">Zoom Video, MicroStrategy And Target Were Among Top 11 Large Cap Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40543907/snowflake-jd-com-and-temu-parent-pdd-are-among-top-8-large-cap-losers-last-week-aug-18-aug-24-are-" target="_blank" rel="noreferrer noopener">Snowflake, JD.com And Temu Parent PDD Are Among Top 8 Large Cap Losers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?

Evolent Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) is reportedly <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">up for sale</a>. 
What Happened: The Arlington, Virginia-based software provide initiated an auction process after receiving takeover inquiries from private equity firms and healthcare providers. 
Among the potential suitors are private equity giants TPG Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), Clayton, Dubilier &amp; Rice (CD&amp;R), and KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>). Notably, TPG was one of Evolent's early investors.
Reuters noted that health insurer Elevance Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) has also expressed interest and may join forces with a private equity partner to pursue a deal.
Founded in 2011, Evolent offers software solutions to help healthcare providers and insurers transition from fee-for-service to value-based care models. The company partners with prominent industry players like Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).
Why It Matters: Evolent has seen financial challenges despite a 38% revenue increase in its latest quarter. The company struggled with lower billing rates from payer customers, leading to results below market expectations.
Its history of attracting acquisition interest includes a 2021 Bloomberg <a href="https://www.bloomberg.com/news/articles/2021-09-29/walgreens-said-to-weigh-takeover-of-evolent-health" target="_blank" rel="noreferrer noopener">report</a> that Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) was considering a deal.
Activist investor Engaged Capital took a significant stake in Evolent in 2020 and pushed for changes to enhance shareholder value.
Price Action: EVH stock is up 0.62% at $32.30 during the premarket session at last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40526625/astrazeneca-threatens-to-move-vaccine-production-amid-reduced-state-support" target="_blank" rel="noreferrer noopener">AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support</a>.</li>
</ul>

Health Care

Rumors

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Evolent Health Explores Sale, Garners Inbound Interest From Private Equity Firms

WIIM

Evolent Health shares are trading higher following a report suggesting that the company is exploring a sale.

Evolent Health Explores Sale Following Acquisition Interest; Potential Bidders Include TPG, CD&R, KKR, And Elevance Health

In the latest quarter, 4 analysts provided ratings for Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Evolent Health, revealing an average target of $37.75, a high estimate of $45.00, and a low estimate of $31.00. Marking an increase of 7.86%, the current average surpasses the previous average price target of $35.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1724072411_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Evolent Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Evolent Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Evolent Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Evolent Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evolent Health analyst ratings.</a>
<h2>About Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Breaking Down Evolent Health's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Evolent Health showcased positive performance, achieving a revenue growth rate of 37.94% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Evolent Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Evolent Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.61%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Evolent Health's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.25%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.6.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 4 Analyst Ratings Have To Say About Evolent Health

JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight and raises the price target from $36 to $45.

JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $45

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday.
Shares of Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) rose sharply during Friday's session after the company reported<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40288024/expedias-q2-triumph-analysts-highlight-vrbo-as-bright-spot-praise-growth-in-busines"> better-than-expected second-quarter financial results.</a>
Expedia Group reported quarterly earnings of $3.51 per share which beat the analyst consensus estimate of $3.06 per share. The company reported quarterly sales of $3.558 billion which beat the analyst consensus estimate of $3.534 billion.
Expedia Group shares jumped 9.4% to $129.02 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Blend Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) gained 32% to $3.55 after the company reported better-than-expected second-quarter financial results. Also, William Blair upgraded the stock from Market Perform to Outperform.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) gained 31.6% to $33.82 after the company reported better-than-expected first-quarter financial results. Additionally, the company issued FY24 revenue guidance above estimates.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) shares surged 29.5% to $15.80 after the company reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) climbed 26.2% to $33.13 after the company reported better-than-expected second-quarter revenue results.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) rose 24.2% to $25.92 after the company reported better-than-expected quarterly financial results. Also, Truist Securities upgraded the stock from Hold to Buy and raised its price target from $28 to $33.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) gained 20.2% to $9.54 after the company reported better-than-expected second-quarter financial results and issued third-quarter product revenue guidance above estimates.</li>
<li>CarGurus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) gained 18.2% to $26.48 after the company reported better-than-expected second-quarter financial results and issued third-quarter non-GAAP EPS guidance above estimates.</li>
<li>IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) gained 15.6% to $4.2550 after the company reported better-than-expected second-quarter financial results.</li>
<li>Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) rose 14.9% to $37.23 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates. Also, the company raised its FY24 EPS guidance above estimates.</li>
<li>Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) climbed 13.7% to $22.19 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>DigitalOcean Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) rose 13.4% to $32.99 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 12.2% to $5.35 after the company reported better-than-expected second-quarter financial results. Also, the company announced it hot fired its new rocket engine Archimedes for the first time.</li>
<li>Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) rose 11.3% to $101.91 after the company reported better-than-expected second-quarter financial results.</li>
<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) gained 10.6% to $46.31.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) rose 9.6% to $96.81 after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates. Also, Keybanc and Susquehanna raised their respective price targets on the stock.</li>
<li>DXC Technology Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) climbed 7.2% to $19.64 after the company reported better-than-expected quarterly financial results..</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) gained 5.8% to $894.83.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/news/24/08/40278354/top-2-risk-off-stocks-that-may-implode-in-august"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40278354/top-2-risk-off-stocks-that-may-implode-in-august">Top 2 Risk Off Stocks That May Implode In August</a></li>
</ul>

Intraday Update

Markets

Trading Ideas

ADMA

AKAM

BLND

CARG

DOCN

DOCS

EXPE

RKLB

Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday

Evolent Health shares are trading higher after the company reported better-than-expected Q2 financial results. Also, Truist Securities upgraded the stock from Hold to Buy and raised its price target from $28 to $33.

JMP Securities analyst Constantine Davides maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform and lowers the price target from $34 to $31.

JMP Securities Maintains Market Outperform on Evolent Health, Lowers Price Target to $31

Truist Securities analyst Jailendra Singh upgrades Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) from Hold to Buy and raises the price target from $28 to $33.

Upgrades

Truist Securities Upgrades Evolent Health to Buy, Raises Price Target to $33

Evolent Health shares are trading higher after the company reported better-than-expected Q2 financial results.

Earnings

Guidance

Evolent Health Sees Q3 2024 Revenue $615M - $635M Vs $636.44M Est.; Sees FY24 $2.56B - $2.6B Vs $2.58B Est.

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.26 by 15.38 percent. The company reported quarterly sales of $647.14 million which beat the analyst consensus estimate of $636.44 million by 1.68 percent. This is a 37.94 percent increase over sales of $469.14 million the same period last year.

Earnings Beats

Evolent Health Q2 2024 Adj EPS $0.30 Beats $0.26 Estimate, Sales $647.14M Beat $636.44M Estimate

Stephens &amp; Co. analyst Jeff Garro reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight and maintains $42 price target.

Stephens & Co. Reiterates Overweight on Evolent Health, Maintains $42 Price Target

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$75.00</td>
<td>$68.9K</td>
<td>5.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$170.00</td>
<td>$121.7K</td>
<td>4.9K</td>
<td>1.2K</td>
</tr>
<tr>
<td>EVH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$28.7K</td>
<td>3.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$240.00</td>
<td>$72.6K</td>
<td>158</td>
<td>867</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$225.00</td>
<td>$25.9K</td>
<td>509</td>
<td>343</td>
</tr>
<tr>
<td>NVAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.00</td>
<td>$100.5K</td>
<td>9.3K</td>
<td>313</td>
</tr>
<tr>
<td>ZVRA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$7.50</td>
<td>$38.7K</td>
<td>3.8K</td>
<td>253</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$550.00</td>
<td>$77.4K</td>
<td>316</td>
<td>250</td>
</tr>
<tr>
<td>IOVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.00</td>
<td>$33.0K</td>
<td>502</td>
<td>150</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$23.00</td>
<td>$69.0K</td>
<td>1.1K</td>
<td>103</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option sweep that happens to be bearish, expiring in 24 day(s) on August 16, 2024. This event was a transfer of 811 contract(s) at a $75.00 strike. This particular put needed to be split into 47 different trades to become filled. The total cost received by the writing party (or parties) was $68.9K, with a price of $85.0 per contract. There were 5564 open contracts at this strike prior to today, and today 2101 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with neutral sentiment. It expires in 115 day(s) on November 15, 2024. Parties traded 234 contract(s) at a $170.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $121.7K, with a price of $520.0 per contract. There were 4997 open contracts at this strike prior to today, and today 1291 contract(s) were bought and sold. 
• For EVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), we notice a call option sweep that happens to be bearish, expiring in 178 day(s) on January 17, 2025. This event was a transfer of 87 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $330.0 per contract. There were 3588 open contracts at this strike prior to today, and today 1000 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bullish sentiment. It expires in 87 day(s) on October 18, 2024. Parties traded 330 contract(s) at a $240.00 strike. This particular put needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $72.6K, with a price of $220.0 per contract. There were 158 open contracts at this strike prior to today, and today 867 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option sweep with bearish sentiment. It expires in 3 day(s) on July 26, 2024. Parties traded 54 contract(s) at a $225.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $25.9K, with a price of $480.0 per contract. There were 509 open contracts at this strike prior to today, and today 343 contract(s) were bought and sold. 
• Regarding NVAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), we observe a call option trade with bullish sentiment. It expires in 178 day(s) on January 17, 2025. Parties traded 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $100.5K, with a price of $670.0 per contract. There were 9360 open contracts at this strike prior to today, and today 313 contract(s) were bought and sold. 
• For ZVRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>), we notice a call option sweep that happens to be bearish, expiring in 115 day(s) on November 15, 2024. This event was a transfer of 250 contract(s) at a $7.50 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.7K, with a price of $155.0 per contract. There were 3801 open contracts at this strike prior to today, and today 253 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a put option trade that happens to be bullish, expiring in 3 day(s) on July 26, 2024. This event was a transfer of 90 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $77.4K, with a price of $860.0 per contract. There were 316 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• Regarding IOVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>), we observe a put option trade with bullish sentiment. It expires in 178 day(s) on January 17, 2025. Parties traded 150 contract(s) at a $9.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $220.0 per contract. There were 502 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with neutral sentiment. It expires in 332 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $23.00 strike. The total cost received by the writing party (or parties) was $69.0K, with a price of $690.0 per contract. There were 1193 open contracts at this strike prior to today, and today 103 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

MRNA

NVAX

ZVRA

10 Health Care Stocks Whale Activity In Today's Session

Evolent To Acquire Certain Assets Of Machinify And The Exclusive, Perpetual And Royalty-Free License Of Machinify Auth; Terms Not Disclosed

Shares of health insurers are trading lower in sympathy with UnitedHealth, which fell after comments at the Bernstein 40th Annual Strategic Decisions Conference.

Evolent Health soars on report of sale talks after inbound interest

In a report released today, Stephanie Davis from Barclays maintained a Buy rating on Evolent Health (EVH – Research Report), with a price target of...

Evolent Health (EVH) Gets a Buy from Barclays

In a report released yesterday, David Larsen from BTIG maintained a Buy rating on Evolent Health (EVH – Research Report), with a price target of $4...

Evolent Health: A Strong Buy Amid Acquisition Interest and Proactive Revenue Strategies

Evolent Health could see $35 a share or more in a takeover - analyst

Evolent Health: Let The Bidding Begin

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY – Research Report) and Evolent ...

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Evolent Health (EVH)

RBC Capital analyst Sean Dodge reiterated a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $42.00. The compan...

Evolent Health (EVH) Gets a Buy from RBC Capital

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Evolent Health (EVH – Research Report). The company's ...

Truist Financial Sticks to Its Buy Rating for Evolent Health (EVH)

Evolent Health dips on report Elevance dropped out of bidding

JMP Securities analyst Constantine Davides has maintained their bullish stance on EVH stock, giving a Buy rating on August 27. Constantine Davides ...

Evolent Health Buy Rating Affirmed with Increased Price Target Amid Growth Prospects and M&A Speculation

ALNY

Offerings

Press Releases

Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan

Evolent to Release Fourth Quarter 2023 Financial Results on Thursday, February 22, 2024

Evolent Adds Russell Glass, Headspace CEO, to Board of Directors

Evolent Announces Fourth Quarter and Full Year 2023 Results

Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Evolent Announces First Quarter 2024 Results

Evolent and Careology form strategic care navigation partnership to enhance cancer care in the U.S.

Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify

Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Evolent Announces Second Quarter 2024 Results

American Well Corporation Class A Common Stock

American Well

Augmedix

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Schrodinger

Sharecare

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

Waystar Holding

Truist Securities

RBC Capital

JP Morgan

JMP Securities

Stephens & Co.

이들 10개의 중형주는 8월에 가장 좋은 성과를 보였다. 이 주식들이 귀하의 포트폴리오에 포함되어 있나요?
1. 폴스타 오토모티브 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>)의 주식이 8월에 74.19% 급등했다. 이는 <a href="https://www.benzinga.com//node/40629765" target="_blank" rel="noreferrer noopener">2분기 강력한 인도량</a>을 발표한 후 발생한 일이다.
2. 업스타트 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)의 주식이 67.32% 급등했다. 이는 회사가 <a href="https://www.benzinga.com//node/40322490" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>을 발표한 후 발생한 일이다.
3. 루멘 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>)의 주식이 58.13% 상승했다. 이는 <a href="https://www.benzinga.com//node/40204727" target="_blank" rel="noreferrer noopener">엇갈린 2분기 실적</a>을 발표한 후 발생한 일이다.
4. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식이 52.46% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener">컨센서스보다 좋은 2분기 주당 손실</a>을 발표한 후 발생한 일다.
5. 템푸스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>)의 주식이 51.17% 상승했다. 이는 주식이 구글과 <a href="https://www.benzinga.com//node/40419923" target="_blank" rel="noreferrer noopener">소프트뱅크 그룹</a>(OTCPK: SFTBF)의 투자로 인해 상승했다.
6. 클리어 시큐어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>)의 주식이 46.81% 상승했다. 이는 <a href="https://www.benzinga.com//node/40181525" target="_blank" rel="noreferrer noopener">예상보다 좋은 분기 실적</a>을 발표한 후 발생한 일이다.
7. 아이오반스 바이오테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>)의 주식이 42.89% 상승했다. 이 회사는 2024년과 2025년을 위한 긍정적인 가이던스를 발표하고 <a href="https://www.benzinga.com//node/40288203" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>을 발표했다.
8. 에볼런트 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>)의 주식이 42.51% 상승했다. 이 회사는 <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">사모펀드와 의료 제공업체들</a>로부터 인수 문의를 받은 후 경매 절차를 시작했다.
9. 셈테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>)의 주식이 42.23% 상승했다. 이는 이 회사가 <a href="https://www.benzinga.com//node/40587744" target="_blank" rel="noreferrer noopener">2분기 실적을 초과 달성</a>했다고 발표한 후 발생한 일이다.
10. AST 스페이스모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)의 주식이 42.07% 상승했다. 이 회사는 <a href="https://www.benzinga.com//node/40398813" target="_blank" rel="noreferrer noopener">9월 초에 5개의 위성을 발사할 예정</a>이라고 발표했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%96%b4%ed%8e%8c-%ec%87%bc%ed%94%bc%ed%8c%8c%ec%9d%b4-%ea%b7%b8%eb%a6%ac%ea%b3%a0-%ec%8a%a4%ed%83%80%eb%b2%85%ec%8a%a4%eb%8a%94-8%ec%9b%94-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4/" target="_blank" rel="noopener">어펌, 쇼피파이 그리고 스타벅스는 8월 최고 성과를 보여준 10개 대형주 중 일부</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%9d%b8%ed%85%94-%eb%aa%a8%eb%8d%94%eb%82%98-%ea%b7%b8%eb%a6%ac%ea%b3%a0-%eb%8b%ac%eb%9f%ac-%ec%a0%9c%eb%84%88%eb%9f%b4%ec%9d%80-8%ec%9b%94-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc/" target="_blank" rel="noopener">인텔, 모더나 그리고 달러 제너럴은 8월 최악의 성과를 보인 10개 대형주 중 일부</a></li>
</ul>
사진 출처: 회사
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다음은 지난주 큰 폭의 상승세를 보인 8개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
1. 루시드 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)의 주식이 32.91% 급등했다. 이 회사는 루시드 파이낸셜 서비시스(Lucid Financial Services)가 <a href="https://www.benzinga.com//node/40466130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">캐나다의 다양한 금융 옵션</a>에 임대를 추가했다고 발표했다. 경제와 금리 인하에 대한 파월 의장의 발언도 심리를 개선했다.
2. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)가 <a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 재무 결과</a>를 보고한 후 주가는 32.04% 상승했다.
3. 프로셉트 바이오로보틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>)가 <a href="https://www.benzinga.com/pressreleases/24/08/g40481411/procept-biorobotics-announces-fda-clearance-of-the-hydros-robotic-system-the-next-generation-ai-po" target="_blank" rel="noopener">자사의 하이드로스 로보틱(HYDROS Robotic) 시스템</a>에 대한 FDA 510(k) 승인을 발표한 후 주가는 22.67% 상승했다.
4. 크레도 테크놀로지 그룹 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>)의 주식이 20.02% 상승했다.
5. 에볼런트 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>)가 <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">매각을 모색하고</a> 있다는 보고서가 나온 후 주가는 19.98% 상승했다.
6. 그리폴스 S.A.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) 주식이 19.50% 급등했다. 이는 브룩필드 에셋 매니지먼트(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/bam" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BAM" data-google-interstitial="false">BAM</a>)가 회사를 인수하기 위해 부채 자금을 모색하고 있다는 보도가 나온 후 발생한 일이다.
7. 뉴발런트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>)의 주식이 19.33% 상승했다.
8. 에이머 스포츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>)가 예상보다 나은 2분기 <a href="https://www.benzinga.com//node/40466836" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">실적을 보고하고 FY24 EPS 전망을 상향</a> 조정한 후 주식이 16.60% 급등했다.
추가로 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%a4%8c-%eb%b9%84%eb%94%94%ec%98%a4-%eb%b0%8f-%ed%83%80%ea%b9%83%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-11%ea%b0%9c-%eb%8c%80/" target="_blank" rel="noopener">줌 비디오 및 타깃은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (8월 18일-8월 24일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%8a%a4%eb%85%b8%ec%9a%b0%ed%94%8c%eb%a0%88%ec%9d%b4%ed%81%ac-%eb%b0%8f-jd%eb%8b%b7%ec%bb%b4-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-8/" target="_blank" rel="noopener">스노우플레이크 및 JD닷컴 지난주 최악의 성과를 보인 8개 대형주 중 일부 (8월 18일-8월 24일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Evolent Health

뉴스

에 대한 최신 뉴스 Evolent Health (NYSE:EVH) 주식

일요일, 9월 08, 2024

일요일, 8월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌